Acotiamide hydrochloride is under clinical development by Zeria Pharmaceutical and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Acotiamide hydrochloride’s likelihood of approval (LoA) and phase transition for Esophageal Motility Disorders took place on 06 May 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Acotiamide hydrochloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Acotiamide hydrochloride overview

Acotiamide hydrochloride (Acofide, YM-443, and Z-338) is a member of a class of prokinetic agents and it is an upper gastrointestinal motility modulator. It is formulated as film-coated tablets for oral route of administration. Acofide is indicated for the treatment of postprandial fullness, upper abdominal bloating, and early satiation due to functional dyspepsia.

It is under development for the treatment of functional dyspepsia and esophageal gastric junction outflow obstruction. The drug candidate acts by targeting acetylcholinesterases. It was also under development for functional dyspepsia in the US and North America.

Zeria Pharmaceutical overview

Zeria Pharmaceutical (Zeria), formerly Zeria Yakusho Kenkyusho, manufactures and distributes pharmaceutical and consumer health care products.The company’s pharmaceutical product range includes drugs for the treatment of ulcerative colitis, Crohn’s disease, functional dyspepsia, gastritis and ulcers and other gastrointestinal diseases. It offers combination granules, calcium channel blockers, anti-leukopenia and iron deficiency anemia agents. Zeria also markets OTC drugs for arthralgia and lumbalgia, physical fatigue and exhaustion and soft drinks. The company owns and operate production facilities in the Switzerland, Denmark, Japan and Vietnam. Zeria is headquartered in Chuo-Ku, Tokyo, Japan.

Quick View Acotiamide hydrochloride LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Acotiamide hydrochloride
Administration Pathway
  • Oral
Therapeutic Areas
  • Gastrointestinal
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.